ST3 beta-Gal alpha-2,3-Sialyltransferase 1 (ST3GAL1) is a sialyltransferase whose overexpression in ovarian cancer cell lines enhances cell growth, migration, and invasion capabilities, as well as increases tumorigenicity and resistance to paclitaxel in vivo. ST3 beta-Gal alpha-2,3-Sialyltransferase 1 catalyzes the transfer of sialic acid from cytidine monophosphate-sialic acid to galactose-containing substrates and can be utilized in studies of cancer progression and chemotherapy resistance[1].
Target-Kategorie:
Endogenous Metabolite
Anwendungsbeschreibung:
MCE Product type: Enzyme
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
